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Objective: To evaluate the predictive values of the expression of factor VIII, CD-34, p53, 
bcl-2, and DNA ploidy regarding the response to chemoradiation of squamous cell carcinoma 
of the esophagus.
Design: Retrospective analysis of pretreatment biopsies with immunohistochemistry and 
ﬂ  ow cytometry. The results were correlated to tumor response (complete vs. noncomplete) 
following chemoradiation with three cycles of 5-FU and cisplatin combined with 40–64 Gy 
of radiation.
Subjects: 44 consecutive patients with squamous cell carcinoma of the esophagus treated with 
chemoradiation with a curative intent from 1992–2000.
Main outcome measures: Treatment response.
Results: No correlations were found between the expressions of p53, bcl-2, or DNA ploidy 
and tumor response to chemoradiation. A positive correlation was found between factor 
VIII expression and a complete tumor response (p = 0.0357). However the other marker for 
angiogenesis, CD-34, showed a negative correlation (p = 0.0493). Both markers indicate 
blood vessel density meaning that, in this study, many vessels indicated a favorable response 
if measured with factor VIII, but a poor response if measured with CD-34.
Conclusion: It is not possible to predict tumor response to our chemoradiation protocol through 
the analysis of pretreatment expression of p53, bcl-2 or DNA ploidy in biopsy specimens. In 
spite of signiﬁ  cant correlations between complete tumor responses and the expressions of the 
markers for angiogenesis this signiﬁ  cance may be questionable since one of the two markers, 
factor VIII had a positive and the other,CD-34, a negative correlation to tumor response.
Keywords: chemoradiation, response, prognostic factor, apoptosis, p-53, angiogenesis, DNA 
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Introduction
Esophageal cancer has a well known poor prognosis.1–3 The 5-year survival has been 
in the order of 5%–10% following surgery or radiotherapy. These poor results have 
stimulated the development of new treatment techniques including more radical 
surgical procedures.4,5
However, at least in the Western countries, esophageal cancer is mostly diagnosed 
at a late disseminated stage. Then locoregional treatments such as surgery and/or 
radiotherapy are insufﬁ  cient to cure the patients. In this situation it is rational to include 
a systemic treatment, ie, chemotherapy into the protocols.
Results of chemotherapy have been poor until the last decade when a number of 
different series of concomitant chemoradiotherapy, mostly including cisplatinum, have 
shown promising results with complete response rates above 40%.6–10.
However these chemoradiotherapy protocols, often in neoadjuvant settings, are 
followed by rather high morbidity and treatment-related mortality.11 It would therefore Clinical and Experimental Gastroenterology 2009:2 42
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be of interest to be able to predict which patient is a responder 
and which is not before the administration of the treatment. 
It would then be possible to exclude nonresponders from a 
potentially harmful treatment.
In this study microbiologic markers have been evaluated 
in two groups of patients, responders and nonresponders, 
treated according to the same chemoradiotherapy protocol.
Angioneogenesis in tumor tissue has been studied, since 
it is known that good oxygenation of tumor cells enhances 
the radiosensitivity and improves the delivery of cytotoxic 
agents.12,13 A high microvessel density with an improved 
circulation enhances this crucial oxygenation. It is however 
also known that angioneogenesis may be a limiting factor 
regarding tumor growth and possibly also regarding the 
tendency to metastasize.14,15 Accordingly a pronounced 
angioneogenesis may both act as an adjunct to chemoradio-
therapy and at the same time be a marker of poor prognosis 
regarding tumor biology. We have investigated pretreatment 
microvessel density within tumors expressed through factor 
VIII and CD-34 and correlated the results to tumor response 
after chemoradiation.
Apoptosis, or programmed cell death, is a physiological 
mechanism regulating homeostasis in both normal and tumor 
tissue by the elimination of unnecessary cells.16 Failure of 
tumor cells to undergo apoptosis can result in uncontrolled 
accumulation of cells. It is known that apoptosis can be 
induced by chemotherapuetic agents and radiation17 and by 
oncogenes such as bcl-2 and p53.18.19 Like a neoplasm with 
fully established tumor cell necrosis, a carcinoma with a high 
incidence of apoptotic nuclei of the neoplastic parenchymal 
cell carcinoma is looked upon as a neoplasm with a bad prog-
nosis for the patient, requiring particular types of therapy. P53 
expression has been correlated to survival in carcinoma of the 
breast,20 colon,21 stomach,22 and lung,23 while the prognostic 
value of p53 in esophageal cancer remains more uncertain.24,25 
Mutations of the tumor suppression antigen p53 are among 
the most commonly detected genetic abnormalities in human 
neoplasia in general and in squamous cell carcinomas in 
particular. The results of an immunohistochemistry (IHC) 
analysis of p53 can govern both the therapy and the prognosis 
of the patient´s carcinoma. It is however a rather well estab-
lished fact that the simple ﬁ  nding of an IHC overexpression 
of some kind, does not yet in itself become a good predictor 
of the subsequent course of the patient’s neoplastic disease. It 
is neither decisive for the choice of therapy. We have studied 
the correlation between tumor response and bcl-2 and p53.
DNA ploidy is known to indicate prognosis in squamous 
cell carcinoma of the esophagus through the detection of 
aneuploid peaks in ﬂ  ow cytometric analysis.26 We have inves-
tigated the pretreatment DNA ploidy and then correlated this 
analysis to the response to chemoradiation therapy.
Patients and methods
Patients
Forty-four patients were recruited from a consecutive 
group of patients, who had received planned preoperative 
or fulldose chemoradiation for squamous cell carcinoma of 
the esophagus during 1992–2000. The patients were sepa-
rated into two groups depending on response to oncological 
therapy (complete response [CR] vs non-CR). See Table 1 
for details.
Eligibility criteria for the study included histologically 
conﬁ  rmed squamous cell carcinoma of the esophagus without 
signs of distant metastases, ie tumor stage T1-4, N0-1, M0 
according to the International Union against Cancer.27 The 
patients had to have a functional performance status of  2 
according to the World Health Organization (WHO) classi-
ﬁ  cation and they should not suffer from any other condition 
that could be worsened by the planned treatment such as 
Table 1 Patient and tumor characteristics
Total CR Non-CR p-value
No. of patients entered 44 23 21
No. of women 23 (52) 11 (48) 12 (57) 0.53 n.s.
Age mean, range 62, 44–82 64, 44–74 60, 45–82 0.23 n.s.
Grade of differentiation
  High 1 (2) 1 (4) – 1.0 n.s.
  Moderate 20 (45) 9 (39) 11 (52) 0.36 n.s.
  Low 23 (53) 13 (57) 10 (48) 0.66 n.s.
Tumor location in 
the esophagus
  Upper 12 (27) 6 (26) 6 (29) 0.85 n.s.
  Middle 19 (43) 9 (39) 10 (48) 0.57 n.s.
  Lower 13 (30) 8 (35) 5 (24) 0.51 n.s.
Tumor length (cm)
   5 14 (32) 8 (35) 6 (29) 0.75 n.s.
   5 to  10 29 (66) 15 (65) 14 (67) 1.0 n.s.
   10 1 (2) – 1 (5) 1.0 n.s.
Tumor stage (UICC)
  IIA 10 (23) 8 (35) 2 (10) 0.07 n.s.
  IIB 1 (2) 1 (4) – 1.0 n.s.
  III 31 (70) 14 (61) 17 (81) 0.12 n.s.
  IV 2 (5) – 2 (10) 0.22 n.s.
Notes: Figures in brackets show percent of group (Total, CR, or non-CR).
Abbreviation: CR, complete response.Clinical and Experimental Gastroenterology 2009:2 43
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serious heart (ie, heart failure or angina) or kidney disorders. 
Hematological and renal function test parameters had to be 
normal (leucocytes  3.0 × 109/L, platelets  100 × 109/L, 
cr-EDTA clearence  65 mL/min). There should not be a 
history of other squamous cell malignancy prior to entry nor 
should there be any history of any type of malignant tumor 
during the last ﬁ  ve years before inclusion. Before entry into 
the study the patients were investigated with spirometry, 
electrocardiogram, barium esophagogram, chest X-ray, com-
puted tomography (CT) scan of the chest and upper abdomen, 
abdominal and endoscopic ultrasound (EUS), esophagoscopy 
with biopsies, and ﬁ  nally bronchoscopy, if the tumor was 
located at or above the carina. Patients with intraluminal air-
way growth were excluded. The results of these pretreatment 
investigations were evaluated by a surgeon and an oncologist 
to ﬁ  nd out if the patients were ﬁ  t for the planned treatment.
Surgical treatment
Before starting the treatment the patients were stratiﬁ  ed as 
primarily resectable or unresectable by the surgeon and the 
oncologist. This stratiﬁ  cation was repeated after the primary 
chemoradiation treatment, when a new CT scan and EUS (if 
available) were performed. The standard surgical technique 
was an Ivor Lewis procedure with a gastric pull-up or with 
a colon interponate as the esophageal substitute.
Oncological treatment
The protocol6 included three ﬁ  ve-day courses of cisplatinum 
(100 mg/m2 on the ﬁ  rst day of each course) and 5-ﬂ  uorouracil 
(a continuous 120-hour infusion on day 1 through 5 of 
each course with 750 mg/m2 administered on each day of 
treatment) with a two-week rest between the treatments. 
Radiation was administered daily on weekdays from the 
ﬁ  rst day of the second course of chemotherapy up to a 
preoperative dose of 40 Gy or through a full dose treatment 
of 64 Gy. The radiation treatment (preoperative or full 
dose) was decided on before the treatment started. The daily 
fractionation was 2 Gy (see Figure 1).
When no tumors were found postoperatively after 
histopathological examination the responses were classiﬁ  ed 
as pathological CR. Patients not operated on were evaluated 
with clinical methods (X-ray of the esophagus, endoscopy, CT 
scans and, when available, EUS). Responses were classiﬁ  ed as 
clinically CR, when no manifestations of malignancy could be 
found with clinical techniques. All other tumors, not classiﬁ  ed 
as complete responses, were grouped together as incomplete 
responses (non-CR) regardless of degree of response.
Biopsy procedure
The biopsies obtained during endoscopies were parafﬁ  n-
embedded and formaldehyde-fixed. These procedures 
were performed at the time of diagnosis. Hence no patients 
had received any anticancer treatment prior to the biopsy 
procedure.
A minimum of three macroscopically representative 
biopsies were sampled from gross tumor tissue through 
an endoscope (various Olympus video gastroscopes) with 
biopsy graspers (Olympus FB-24K®).
RESECTION 
RT (40 Gy) 
RT  (24 Gy) 
Week   
1           2          3          4          5          6         7   
CHEMO
2
CHEMO
3
CHEMO
1
Figure 1 Oncological treatment protocol.
Abbreviations: Chemo, chemotherapy; RT, radiotherapy.Clinical and Experimental Gastroenterology 2009:2 44
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Laboratory methods
Factor VIII, CD-34, p53 and bcl-2 were all analyzed 
according to standard immunohisto-chemistry methods 
utilizing the avidin biotinylated immunoperoxidase-staining 
technique (Hsu 28). The reason why factor VIII and CD34 
were chosen as IHC markers for angiogenesis was the fact 
that among the antisera raised against endothelial cells avail-
able in our laboratory, these were found to be those which in 
pilot studies showed themselves to give the histotechnically 
most optimal results.
A standardized procedure for cutting out specimens from 
the large resection material for subsequent light microscopy 
was applied. Particular attention was paid to visualize the free 
borders of the specimen. This was performed by marking 
them with India ink.
The sections were deparaffinated in xylene and 
rehydrated in ethanol and distilled water. Antigen retrieval 
was performed through pressure boiling for two minutes 
in 10 mM citrate buffer (factor VIII, CD-34, p-53, and bcl-2) 
and through digestion with proteinase K (DAKO, code 2019) 
(factor VIII). They were then immunostained (see Table 2 for 
primary antibodies) and endogenous peroxidase activity 
was blocked with hydrogen peroxide before exposure to 
biotinylated secondary linking antibody, avidin-biotinylated 
enzyme complex, diaminobenzidine (DAB) as chromogen 
and hematoxylin as counterstain.
Two independent experienced histopathologists (SF, UF) 
then evaluated the specimens. They did not know the clinical 
outcome of the individual patients.
The evaluations were performed in light microscopy in 
400 × magniﬁ  cation ﬁ  elds. All tumor tissue was evaluated, 
excluding the stroma. An average ﬁ  gure from each section 
was calculated.
Factor VIII
The number of microvessels in each ﬁ  eld was calculated. 
Stains were counted as microvessels when they were not 
associated with the muscular bundles of arteries or arteriole. 
A lumen was not necessary for a positive count. Vessels in 
and along the borders of tumor tissue were counted.
CD-34
CD-34 was calculated in the same way as factor VIII.
Bcl-2
One or more stained cells in a biopsy were regarded as a 
positive case. The evaluation was performed at both 100 × 
and 400 × magniﬁ  cation.
P-53
More than 50% positively stained cells out of the total were 
regarded as a positive case. The evaluation was performed 
at both 100 × and 400 × magniﬁ  cation.
DNA
The utilized procedure in the analysis of DNA-ploidy was 
ﬂ  ow cytometry. This analysis was only performed with 
specimens from the ﬁ  rst consecutive 28 patients due to 
technical difﬁ  culties.
Statistical considerations
The continuing variables have been analyzed with logistic 
regression and divided into different categories according 
to different value cut-offs. The category variables have 
been analyzed in cross tables with Fisher’s test and the 
Chi-squared test.
Ethical considerations
The study was approved by the ethics committee at the 
Karolinska Institute in Stockholm. All living patients gave 
their informed consent to take part in the study.
Results
Oncological therapy
Twenty-three patients had complete responses (the CR 
group), while the other 21 patients (the non-CR group) 
showed poorer responses (partial responses or less). 
See Table 3 for details. In accordance with other studies6 
response to chemoradiation was correlated to initial tumor 
stage (p   0.05).
All 44 patients received  40 Gy of radiation and three 
courses of chemotherapy. Four patients, two from each group, 
received full dose radiation.
Surgery
Thirty-ﬁ  ve of the 44 patients were operated on (80%). 
Five patients did not receive any operation due to a high 
location in the esophagus. High tumors were not resected 
to avoid mutilating laryngectomies. Two patients were not 
Table 2 Primary antibodies used during immunohistochemistry
Investigated marker Antibody Manufacturer
Factor VIII A082 DAKO
CD-34 NCL-END Novo Castra
Bcl-2 M887 DAKO
P-53 NCL-CM1 Novo CastraClinical and Experimental Gastroenterology 2009:2 45
Chemoradiatiotherapy in squamous cell carcinoma of the esophagus
operated on because of local overgrowth on adjacent organs. 
Finally two patients, initially planned for surgery, were not 
operated due to poor health following oncologic treatment. 
In the non-CR group of patients three cases of unexpected 
advanced tumor growth was found during operation and 
therefore only explorations were performed. Eighteen 
of the 23 patients (78%) in the CR group had resections 
compared to 14 of 21 patients (67%) in the non-CR group. 
See Table 4 for details.
Angiogenetic markers in CR 
vs non-CR groups
Factor VIII
A statistically signiﬁ  cant difference was found between 
responders and nonresponders regarding vessel density in 
tumor tissue expressed as mean numbers of vessels stained 
for factor VIII/ﬁ  eld of vision (p = 0.0357).
CD-34
A weak negative correlation (p = 0.0493) was found when 
the vessel density was calculated with the CD-34 method as 
opposed to the results of the factor VIII evaluations.
Apoptosis
Bcl-2
Seven patients in the CR group had positive stains for 
bcl-2 as did ﬁ  ve patients in the non-CR group. All other 
patients were negative. As a consequence no signiﬁ  cant 
difference was found between the two groups regarding bcl 
expression.
P-53
No signiﬁ  cant differences were found between responders 
and nonresponders regarding p-53 expression (p = 0.895).
DNA-ploidy
DNA
Most of the 28 analyzed tumors were aneuploid (n = 25). Two 
tumors in the CR group (n = 14) of patients were tetraploid, as 
was one of the tumors in the non-CR group (n = 14). Hence no 
difference in DNA-ploidy was found between the groups.
Discussion
Tumor angiogenesis has been shown to relate to survival 
in a number of different tumors including squamous cell 
carcinoma of the esophagus.29 The same relation has also 
been shown regarding the expression of p-5325 and apoptosis 
through bcl-2.30
A few investigators have adressed the same issue as in our 
study, ie, to ﬁ  nd predictors of tumor response to demanding 
oncological therapy. The rationale is to make it possible to 
avoid the often serious side effects of a demanding and, in 
the case of the non responders, ineffective treatment.
Imdahl and colleagues31 found a better response to 
chemoradiation in tumors with a high proliferation rate 
determined by MIB-1 immunohistology, but no such correla-
tion was found in their series investigating tumor response 
and apoptosis. Seitz and colleagues32 found correlations 
between clinical response (endoscopy with biopsies two to 
three weeks after chemoradiation) and lack of p53 overex-
pression. DNA ploidy (ﬂ  ow cytometry) and cell prolifera-
tion (Ki67) was not correlated to tumor response. Ressiot 
and colleagues, on the other hand, found overexpression of 
Ki67 to be an independent factor for complete response in 
esophageal cancer.33 Sarbia and colleagues34 found that the 
expression of cyklin D1 was correlated to a poor response 
to radiochemotherapy but this correlation was not found in 
overall survival. The same authors have also investigated 
bcl-2 and p53 in radiochemotherapy treated patients without 
ﬁ  nding a signiﬁ  cant correlation to tumor response.35
Table 3 Responses and survival following therapy
Total CR group Non-CR group
Response
  Complete, clinical 5 (11) 5 (22) –
  Complete, pathological 18 (41) 18 (78) –
  Partial, clinical 2 (5) – 2 (10)
  Partial, pathological 11 (25) – 11 (52)
  Stable disease 3 (7) – 3 (14)
  Progressive disease 5 (11) – 5 (24)
Median survival (months) 24.3 42.3 16.8
Notes: Figures in brackets show percent of group (Total, CR, and nonCR).
Abbreviation: CR, complete response.
Table 4 Delivered treatment
Gy Courses 
of CT
Total CR Non-CR
Oncologic treatment
40 3 40 (91) 21 (91) 19 (90)
 40 3 4 (9) 2 (9) 2 (10)
Surgical treatment
  Operations 35 (80) 18 (78) 17 (81)
  Resections 32 (73) 18 (78) 14 (67)
  Explorations 3 (7) – 3 (14)
Notes: Figures in brackets show percent of group (Total, CR, and non-CR).
Abbreviations: CR, complete response; CT, computed tomography.Clinical and Experimental Gastroenterology 2009:2 46
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Shimada and colleagues found a correlation between low 
angiogenetic activity, expressed through low serum vascular 
endothelial growth factor levels, and a good tumor response 
in squamous cell carcinoma of the esophagus.36 This ﬁ  nding 
was supported by the study by Imdahl.37
COX-2 displays antiapoptotic functions related to angio-
genesis or blocking of bcl-2 action. Takatori and colleagues 
found that COX-2 mRNA expression in tumor biopsies 
was closely related to chemoradiotherapy effectiveness in 
esophageal squamous cell carcinoma.38
In our study correlations between angiogenesis and tumor 
response were found. There were no correlations between 
apoptosis (bcl-2), p-53 expression or DNA ploidy and the 
response to chemoradiation. Shimada did not ﬁ  nd any cor-
relation between p-53 and tumor response either,39 but these 
results were challenged by earlier studies by Ribiero40 and 
Yang.41 One major problem with the results of our study 
was that the two markers of angiogenesis, factor VIII and 
CD-34 were correlated to response, but not in the same way. 
Factor VIII had a signiﬁ  cant positive correlation at the 5% 
level with a p-value of 0.0357 whereas CD-34 had a slight 
signiﬁ  cant negative correlation with a p-value of 0.0493. One 
explanation for this lack of correlation may be the fact that VIII 
also is known to be a marker of lymphangiogenesis.
Squamous cell carcinomas of the esophagus have an 
intratumoral heterogeneity that may inﬂ  uence the represen-
tativeness of the biopsies harvested. It has been shown that 
heterogeneity is less pronounced in different parts of the same 
tumor compared with samples from different tumors.42 It is 
therefore unlikely that our method of sampling can explain 
the results.
The method of pressure cooking to achieve antigen 
retrieval during the IHC process is sensible and it has to be 
performed with caution. However the fact that both positive 
and negative stains were found after pressure cooking and 
that the controls utilized were colored as expected supports 
the accuracy of the method.
Finally it has to be noted that the group of patients was 
relatively small which may inﬂ  uence the results. However 
it must be concluded that no major differences can be found 
regarding apoptosis, p-53 or DNA ploidy if a CR group 
is compared with a non-CR group in chemoradiation of 
squamous cell carcinoma of the esophagus. Neither can it 
be concluded that angiogenesis is a predictor of therapeutic 
success with the chemoradiation protocol used, since the 
two markers of angiogenesis show diverse correlations. 
An unknown procedure related, or biologically determined 
factor may be responsible for this. It has however to be 
noted that other studies, as demonstrated above, do not show 
unequivocal results.
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